Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC
April 15th 2023A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.
Read More
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist
April 13th 2023Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.
Read More
Ixazomib Shows PFS Benefit Across Age and Frailty Subgroups in Multiple Myeloma
April 12th 2023A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.
Read More
DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes
April 8th 2023A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.
Read More
ICER White Paper Recommends Health Technology Assessment Strategies to Improve Care Equity
April 7th 2023A white paper published by the Institute for Clinical and Economic Review (ICER) established a series of recommendations and guidelines for health technology assessment that aim to address health care disparities.
Read More
Study Links Early Pet Exposure, Reduced Food Allergy Incidence in Japanese Children
April 7th 2023Exposure to pets during fetal development or early infancy was associated with reduced instances of food allergies in young children, with different pet exposures potentially reducing the incidence risk of certain allergen types.
Read More
Sublobar Resection Produces Similar Outcomes to Lobectomy in Early NSCLC
April 5th 2023Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.
Read More
Ide-Cel Shows Benefit vs Standard Regimens in Heavily Pretreated R/R Multiple Myeloma
March 30th 2023Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.
Read More
Immunotherapy for NSCLC Safe in Elderly Patients, but More Research Needed
March 30th 2023A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).
Read More
Study Characterizes Infections in Patients Treated With Bispecific Antibodies for Multiple Myeloma
March 23rd 2023A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits.
Read More
Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL
March 21st 2023A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).
Read More
Racial, Ethnic, Socioeconomic Disparities Identified Among Patients With Cachexia at NSCLC Diagnosis
March 15th 2023A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups.
Read More
Stops and Starts Abound in the Oncology Payment Landscape
March 10th 2023A session at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and payment, from the Cures 2.0 Act to 340B drug reimbursement.
Read More
Multicancer Early Detection May Change the Screening Game—If We Learn From the Past
March 9th 2023A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.
Read More
Lenvatinib Plus Pembrolizumab Shows Durable Efficacy Benefits vs Sunitinib in Renal Cell Carcinoma
March 8th 2023The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.
Read More
ACCC Meeting to Highlight Technological Advances and Care Delivery Models in Oncology
March 6th 2023The Association of Community Cancer Centers (ACCC) 49th Annual Meeting and Cancer Center Business Summit will feature presentations and interactive workshops centered on the latest in technology, care delivery, and payment issues in oncology.
Read More